Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded.
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Matinas BioPharma Holdings, Inc (NYSEAMERICAN:MTNB) Shares Sold by Staley Capital Advisers Inc themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Matinas Biopharma Successfully Reaches Agreement With FDA For A Single Phase 3 Registration Trial To Support An NDA For MAT2203 For The Treatment Of I menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.